nantkwest

NATURAL KILLER CELLS: THE QUEST TOWARDS A CURE

Living Drugs in a Bag® therapy

OUR WAR AGAINST CANCER

Harnessing Nature’s Immune System
COVID-19 updates:
Learn how NantKwest is responding to Coronavirus as well as additional information & resources.

The World’s First Off The Shelf Genetically

Engineered Natural Killer Cell Platform

Meet our NK Cells

haNK®

Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high binding affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody.

haNK

taNK®

Chimeric Antigen Receptor directed killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.

taNK

t-haNK™

Our newest line of investigational products are an innovative combination of our haNK and taNK platforms in a single genetic engineered platform that incorporates all the features of our haNK platform together with a CAR with the resulting
t-haNK designed to avail itself of all three modes of killing: innate, antibody mediated and Chimeric Antigen Receptor (CAR) directed killing.

t-haNK
previous arrow
next arrow
Slider

The World’s First Off The Shelf Genetically Engineered Natural Killer Cell Platform

Meet our NK Cells

haNK®

Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high binding affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody.

taNK®

Chimeric Antigen Receptor directed killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.

t-haNK™

Our newest line of investigational products are an innovative combination of our haNK and taNK platforms in a single genetic engineered platform that incorporates all the features of our haNK platform together with a CAR with the resulting t-haNK designed to avail itself of all three modes of killing: innate, antibody mediated and Chimeric Antigen Receptor (CAR) directed killing.

Recent News

Hoag Offers Clinical Trial for Pancreatic Cancer Patients

Hoag has been exclusively selected as the only hospital in Orange County, and the only non-academic institution, to offer this promising phase 2 immunotherapy clinical trial for solid tumors. NEWS PROVIDED BY Hoag Memorial Hospital Presbyterian Aug 05, 2020, 14:28 ET...